In this news, we discuss the South Africa’s Aspen agrees with J&J to manufacture COVID-19 vaccine candidate.
JOHANNESBURG (Reuters) – South African pharmaceutical company Aspen Pharmacare APNJ.J said on Monday it had reached a preliminary agreement with Johnson & Johnson JNJ.N to commercially manufacture its COVID-19 vaccine candidate.
Aspen said he has agreed to provide the capacity required to manufacture J & J’s vaccine candidate, which is still in clinical trials, at its plant in Port Elizabeth.
Aspen will do the formulation, filling and secondary packaging of the vaccine for the supply of Johnson & Johnson, the company said.
Reporting by Tanisha Heiberg; Editing by Alexander Winning
Original © Thomson Reuters